MTOR and neoplasm: Since PD-L1 promotes Akt/mTOR activation and glycolysis in tumor cells, it is suggested that checkpoint blockade therapy may correct the metabolic competition-mediated nutrient availability imbalance between T cells and tumor cells through a direct effect on the tumor cells (82) (Figure 1; Table 1).